Dacomitinib Found Not to Improve Overall Survival in Patients with Advanced NSCLC
Dacomitinib was not effective at improving overall survival in advanced non-small cell lung cancer (NSCLC).
Diagnosis & Disease Information
For Non-Small Cell Lung Cancer (NSCLC), VAL-083 Demonstrates Effectiveness
VAL-083 was shown to be superior to cisplatin for the treatment of non-small cell lung cancer.
Improving Survival in Advanced NSCLC: Multiple Lines of Chemotherapy Make a Difference
Oncologists who care for non-small cell lung cancer (NSCLC) patients need to develop management strategies.
For Non-Small Cell Lung Cancer (NSCLC) Refractory to Crizotinib, Alectinib May Be Effective
Alectinib may be effective treatment for patients with non-small cell lung cancer (NSCLC), refractory to crizotinib.
For Some Patients with Stage 4 Non-Small Cell Lung Cancer (NSCLC), Aggressive Treatment Improves 5-Year Survival
Aggressive treatment for low-risk stage 4 non-small cell lung cancer (NSCLC) results in a 5-year overall survival rate of 47.8%.
In Patients With Advanced Non-Small Cell Lung Cancer, BIM Deletion Decreases Survival
BIM deletion in advanced non-small cell lung cancer is associated with shorter progression free survival.
ZYKADIA™ (ceritinib)
This slideshow reviews drug information for ZYKADIA™ (ceritinib), indicated for anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC). Table of Contents Slide 3: Indication, Dosage, and AdministrationSlide 9: Use in Specific PopulationsSlide 11: Clinical PharmacologySlide 15: Warnings and PrecautionsSlide 19: Clinical Safety and EfficacySlide 24: Drug Storage and Supply
Novel TAZ-targeted Therapy to Fight Against Non-Small Cell Lung Cancer
High transcriptional coactivator with PDZ-binding motif levels may be markers of poor prognosis non-small cell lung cancer.
Protein Test Predicts Survival Benefit of Chemo vs. Erlotinib
For patients with non-small cell lung cancer, a new proteomic test can predict who will benefit from chemotherapy versus erlotinib.
Afatinib + Paclitaxel Effective in EGFR Inhibitor-resistant Lung Cancer
CHICAGO, IL— Non-small cell lung cancer tumors that progress on the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib/gefitinib and afatinib continue to depend on ErbB family receptor signaling.
- Loading...
Loading...
Next post in ASCO 2014
Loading... 
Loading...